Methimazole vs Propylthiouracil (PTU): Hyperthyroidism Treatment Compared

Hyperthyroidism—a condition characterized by excessive production and secretion of thyroid hormones by the thyroid gland—affects approximately 1.2% of the population in the United States, with Graves’ disease accounting for 60–80% of cases. Untreated or inadequately treated hyperthyroidism can lead to serious complications including atrial fibrillation, heart failure, osteoporosis, and in severe cases thyroid storm—a life-threatening medical emergency.

Antithyroid drugs are the mainstay of medical therapy for hyperthyroidism, with two agents dominating clinical practice: methimazole (Tapazole) and propylthiouracil (PTU). Both drugs suppress thyroid hormone synthesis by inhibiting the enzyme thyroid peroxidase (TPO), but they differ in important ways that influence clinical decision-making. This comprehensive comparison examines the pharmacology, efficacy, safety, and practical considerations of both agents.

Understanding Hyperthyroidism and the Role of Antithyroid Drugs

Hyperthyroidism results from a disruption of the normal feedback loop that regulates thyroid hormone production. In Graves’ disease—the most common cause of hyperthyroidism—autoantibodies (thyroid-stimulating immunoglobulins, or TSIs) bind to and activate the TSH receptor on thyroid follicular cells, driving excessive production of thyroxine (T4) and triiodothyronine (T3). Other causes include toxic multinodular goiter, toxic adenoma, subacute thyroiditis (which releases pre-formed hormone rather than increasing synthesis), and drug-induced hyperthyroidism.

The clinical manifestations of hyperthyroidism reflect the widespread effects of thyroid hormones on metabolism: weight loss despite increased appetite, heat intolerance and sweating, tachycardia and palpitations, tremor, anxiety and irritability, insomnia, frequent bowel movements, and in Graves’ disease, ophthalmopathy (proptosis, periorbital edema, and extraocular muscle dysfunction). Antithyroid drugs are used to restore euthyroidism by inhibiting new hormone synthesis. They do not remove pre-formed hormone or directly address the autoimmune process, but they control the hyperthyroid state while longer-term treatment strategies are planned or while awaiting spontaneous remission in Graves’ disease.

What Is Methimazole?

Methimazole (brand name Tapazole, also available as generic) is a thionamide antithyroid drug that was introduced in the 1950s and has become the most widely prescribed antithyroid medication worldwide. Methimazole is a synthetic compound that is structurally related to the thionamide class, which also includes carbimazole (available in the UK and some other countries—a prodrug that is rapidly converted to methimazole in the body).

Methimazole works by inhibiting thyroid peroxidase (TPO), the key enzyme responsible for the oxidation of iodide, the organification of iodide to tyrosine residues on thyroglobulin, and the coupling of iodotyrosines to form T4 and T3. By blocking TPO, methimazole reduces the production of both T4 and T3. It does not affect the release of pre-formed hormone from the thyroid gland, which is why it takes several weeks for thyroid hormone levels to normalize after starting treatment—the existing hormone stores must be depleted naturally.

Methimazole is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations reached within 1–2 hours. It has a half-life of approximately 6–8 hours but its inhibitory effect on the thyroid gland lasts much longer, permitting once-daily or twice-daily dosing. Methimazole is available in 5 mg and 10 mg tablets. The typical starting dose for hyperthyroidism ranges from 10–30 mg daily, depending on the severity of the hyperthyroidism and the size of the thyroid gland.

What Is Propylthiouracil (PTU)?

Propylthiouracil (PTU, brand name Propacil, generic) is another thionamide antithyroid drug, introduced in the 1940s. Like methimazole, PTU inhibits thyroid peroxidase (TPO) and thus reduces the synthesis of T4 and T3. However, PTU has an additional pharmacological action that distinguishes it from methimazole: it also inhibits the peripheral conversion of T4 to T3 by blocking the type 1 deiodinase enzyme in extrathyroidal tissues such as the liver, kidney, and skeletal muscle.

This inhibition of peripheral T4-to-T3 conversion gives PTU a theoretical advantage in situations where rapid reduction of active thyroid hormone levels is needed—most notably in thyroid storm, the life-threatening exacerbation of hyperthyroidism. By blocking both new hormone synthesis (via TPO inhibition) and the activation of circulating T4 to T3 (via deiodinase inhibition), PTU can more rapidly reduce the concentration of biologically active T3.

PTU is well absorbed orally, with peak plasma concentrations reached within 1–2 hours. Its half-life is relatively short—approximately 1–2 hours—but like methimazole, its pharmacodynamic effect on the thyroid persists beyond its plasma half-life, allowing for dosing every 6–8 hours. PTU is available in 50 mg tablets. The typical starting dose for hyperthyroidism ranges from 100–300 mg daily in divided doses (typically every 6–8 hours).

Mechanism of Action: Detailed Comparison

Both methimazole and PTU act primarily through inhibition of thyroid peroxidase (TPO), the heme-containing enzyme located at the apical membrane of thyroid follicular cells. TPO catalyzes three critical steps in thyroid hormone synthesis:

1. Iodide oxidation: TPO oxidizes iodide ions (I-) to elemental iodine (I2 or I+), making them reactive enough to bind to tyrosine residues.
2. Organification: TPO attaches the oxidized iodine to the tyrosine residues on thyroglobulin, forming monoiodotyrosine (MIT) and diiodotyrosine (DIT).
3. Coupling: TPO couples MIT and DIT to form T3 (MIT + DIT = T3) and T4 (DIT + DIT = T4).

By inhibiting TPO, both drugs block these steps, reducing the production of new T4 and T3. However, neither drug affects the release of pre-formed and stored thyroid hormone, which explains why the antithyroid effect is gradual—thyroid hormone levels typically take 1–3 weeks to begin declining and 4–8 weeks to reach normal ranges.

The key difference: PTU uniquely inhibits the type 1 iodothyronine deiodinase (D1) enzyme in peripheral tissues, which converts T4 to the more potent T3. This provides PTU with a dual mechanism—blocking both T4/T3 synthesis and T4-to-T3 conversion—that methimazole does not possess. In clinical practice, the significance of this difference is debated: while PTU’s peripheral conversion blockade is theoretically advantageous in thyroid storm, the magnitude of T3 reduction from this mechanism alone is modest, and other therapies (beta-blockers, corticosteroids, iodine) also contribute to managing thyroid storm.

Dosing Schedule Comparison

Parameter	Methimazole	Propylthiouracil (PTU)
Available strengths	5 mg, 10 mg tablets	50 mg tablets
Typical starting dose (mild-moderate hyperthyroidism)	10–20 mg once daily or divided BID	100–150 mg daily in divided doses (every 6–8 hours)
Typical starting dose (severe hyperthyroidism / large goiter)	30–40 mg once daily or divided BID	200–300 mg daily in divided doses (every 6–8 hours)
Maintenance dose	5–15 mg once daily	50–150 mg daily in divided doses
Dosing frequency	Once daily or BID (more convenient)	Every 6–8 hours (TID or QID — less convenient)
Time to peak plasma	1–2 hours	1–2 hours
Plasma half-life	6–8 hours	1–2 hours
Duration of thyroid inhibition (pharmacodynamic)	Longer (supports once-daily dosing)	Shorter (requires more frequent dosing)
Food effect	Can be taken with or without food	Can be taken with or without food

Efficacy: Which Drug Controls Hyperthyroidism Better?

Multiple randomized controlled trials and systematic reviews have compared methimazole and PTU for the treatment of hyperthyroidism, and the overall evidence indicates that both drugs are effective, with methimazole having some practical advantages.

Speed of biochemical control: Some studies suggest that methimazole achieves normalization of thyroid function tests (TSH, free T4, total T3) slightly faster than PTU at equivalent doses, likely due to methimazole’s longer half-life and more sustained TPO inhibition. However, the difference is modest—typically 1–2 weeks—and both drugs produce comparable rates of biochemical remission at standard doses.

Remission rates in Graves’ disease: In Graves’ disease, the goal of antithyroid drug therapy is to achieve remission—defined as sustained euthyroidism after discontinuation of the drug, without the need for radioactive iodine or surgery. Remission rates with antithyroid drugs are approximately 30–50% after 12–18 months of treatment, with higher rates in patients with mild disease, small goiters, and lower baseline thyroid hormone levels. There is no clear evidence that one drug produces higher remission rates than the other—both appear similar in this regard.

Thyroid storm: PTU has historically been preferred over methimazole in thyroid storm because of its dual mechanism (TPO inhibition plus peripheral T4-to-T3 conversion blockade). However, contemporary guidelines increasingly accept methimazole as an alternative in thyroid storm when PTU is not available or contraindicated, especially given methimazole’s more convenient dosing and better safety profile. The 2016 American Thyroid Association (ATA) guidelines state that either methimazole or PTU can be used in thyroid storm, with PTU traditionally preferred but methimazole being an acceptable option.

Side Effects and Safety Profiles

Both methimazole and PTU share a similar side effect profile, as they belong to the same drug class. Adverse effects are broadly classified into minor (more common) and major (less common but potentially serious) categories.

Minor side effects (occurring in approximately 5–15% of patients, similar for both drugs):

• Skin reactions: Rash, urticaria (hives), and pruritus are the most common minor side effects. They typically occur within the first few weeks of treatment and are often self-limiting. Methimazole is more commonly associated with skin reactions than PTU in some studies.
• Arthralgia and myalgia: Joint and muscle pain reported in 2–5% of patients.
• GI upset: Nausea, vomiting, and loss of appetite—more common at higher doses. Taking the medication with food can help mitigate these effects.
• Metallic taste: Reported by some patients, more commonly with methimazole.
• Hair thinning: Transient hair loss can occur during the initial months of treatment as the hair cycle adjusts to the changing thyroid hormone levels. This is usually temporary and resolves as euthyroidism is restored.
• Slight goiter enlargement: A transient increase in goiter size can occur due to TSH elevation during the titration phase.

Major side effects — shared by both drugs:

• Agranulocytosis: A potentially life-threatening reduction in white blood cells (especially neutrophils), occurring in approximately 0.2–0.5% of patients. This is the most serious adverse effect of antithyroid drugs. Agranulocytosis typically presents within the first 2–3 months of treatment with symptoms of severe sore throat, fever, and signs of infection. It can progress rapidly to overwhelming infection and sepsis if not promptly recognized and treated. The incidence is similar for methimazole and PTU, though some studies suggest a slightly higher risk with PTU at higher doses. Patients must be counseled to immediately report any signs of infection (especially sore throat or fever) and to stop the drug and seek medical attention. A baseline complete blood count (CBC) with differential is recommended before starting treatment, but the white blood cell count cannot reliably predict who will develop agranulocytosis, as it is an idiosyncratic reaction rather than a dose-dependent toxicity.
• Hepatotoxicity: Both drugs can cause liver injury, ranging from mild transaminase elevations to severe hepatotoxicity with jaundice, liver failure, and death. PTU has been associated with a higher incidence of severe hepatotoxicity than methimazole, particularly in children. The FDA has issued a black box warning for PTU regarding the risk of severe liver injury and acute liver failure. Methimazole hepatotoxicity is typically cholestatic, while PTU hepatotoxicity tends to be hepatocellular—a distinction with some prognostic implications.
• Vasculitis: Both drugs, but particularly PTU, have been associated with ANCA-positive vasculitis (antineutrophil cytoplasmic antibody-associated vasculitis), which can present with fever, skin lesions, joint pain, pulmonary infiltrates, and renal involvement. This is a rare but recognized serious adverse effect.
• Birth defects: Methimazole has been associated with a specific pattern of birth defects when taken during the first trimester of pregnancy, known as methimazole embryopathy. This includes choanal atresia (nasal passage closure), esophageal atresia, scalp defects (aplasia cutis congenita), and facial dysmorphism. The risk is small (estimated at 2–4% of exposed pregnancies) but clinically significant. PTU has traditionally been considered safer in pregnancy, particularly during the first trimester, and is the preferred antithyroid drug during early pregnancy. However, PTU also carries some teratogenic risk, albeit lower than methimazole.
• PTU-specific: Severe hepatotoxicity: As noted above, PTU carries an FDA black box warning for severe liver injury and acute liver failure, which can occur at any time during treatment and can be fatal. This risk is particularly pronounced in children, leading to a recommendation that PTU generally be avoided in the pediatric population except in specific circumstances (first-trimester pregnancy, methimazole allergy, or thyroid storm).

Pregnancy Safety: A Critical Decision Point

The choice between methimazole and PTU in pregnancy is one of the most important clinical decisions in hyperthyroidism management, given the teratogenic risks of both drugs and the potential harm of uncontrolled hyperthyroidism to both mother and fetus.

First trimester (weeks 1–12): PTU is the preferred antithyroid drug during the first trimester, based on the lower risk of methimazole embryopathy. The ATA guidelines recommend that women on methimazole who are planning pregnancy or discover they are pregnant should be switched to PTU as soon as possible, ideally within the first 6–10 weeks of gestation. However, if a patient is already stable on PTU from a previous pregnancy, many clinicians continue PTU throughout the first trimester.

Second and third trimesters (weeks 13+): After the first trimester, the risk of methimazole embryopathy is no longer relevant (organogenesis is complete), and many clinicians switch back to methimazole due to its more convenient dosing (once daily vs. multiple daily doses for PTU), better tolerability, and lower risk of hepatotoxicity. The lowest effective dose should be used throughout pregnancy to minimize the risk of fetal goiter and hypothyroidism.

Important note: Both methimazole and PTU cross the placenta and can cause fetal goiter and hypothyroidism if the dose is too high. Serum thyroid hormone levels should be monitored every 2–4 weeks during pregnancy, and doses should be adjusted to maintain maternal free T4 at the upper limit of the normal range or slightly above. This is because mild maternal hyperthyroidism is preferable to fetal hypothyroidism from overtreatment. Additionally, in pregnant women with Graves’ disease, TSIs (thyroid-stimulating immunoglobulins) cross the placenta and can cause neonatal Graves’ disease, even in women who have been treated and are euthyroid. Neonates of mothers with Graves’ disease require careful monitoring of thyroid function after birth.

Clinical Scenarios: When Is Each Drug Preferred?

Methimazole is the preferred first-line agent in most non-pregnant adults because:

• Once-daily dosing improves adherence.
• Lower risk of hepatotoxicity compared to PTU.
• Better tolerability in many patients.
• Longer track record of safe use outside of pregnancy.
• More convenient for long-term treatment (12–18 months for Graves’ disease remission induction).

PTU is preferred in the following scenarios:

• First trimester of pregnancy: Due to the lower risk of methimazole embryopathy.
• Thyroid storm (traditional preference): Due to the theoretical advantage of peripheral T4-to-T3 conversion blockade, though methimazole is an accepted alternative.
• Methimazole allergy or intolerance: When a patient cannot tolerate methimazole due to rash or other side effects, PTU is the alternative (with appropriate counseling about the hepatotoxicity risk).
• Patients requiring rapid biochemical control in specific circumstances: Though the evidence is mixed, some clinicians prefer PTU when a very rapid reduction in T3 is desired, such as in severe cardiac complications of hyperthyroidism.
• Patients who prefer divided dosing: Although not a clinical indication, some patients prefer the divided dosing of PTU if they experience fewer side effects with smaller individual doses (though methimazole can also be divided).

Drug Interactions

Both methimazole and PTU have relatively few drug-drug interactions compared to many other medications, but several important interactions must be considered.

Important interactions for both drugs:

• Warfarin: Thionamide antithyroid drugs can potentiate the anticoagulant effect of warfarin, likely by reducing the metabolism of vitamin K-dependent clotting factors (since thyroid hormones increase the metabolism of vitamin K-dependent factors, their reduction by antithyroid drugs can increase clotting factor levels relative to the warfarin effect). Prothrombin time (PT/INR) should be monitored more frequently when starting or adjusting antithyroid drug doses in patients on warfarin.
• Beta-blockers: Beta-blockers (e.g., propranolol, atenolol, metoprolol) are often used in hyperthyroidism to control adrenergic symptoms (tachycardia, tremor, anxiety) and do not directly interact with antithyroid drugs. However, they are frequently co-prescribed and the combination should be monitored for excessive bradycardia or hypotension.
• Corticosteroids: Corticosteroids are used in thyroid storm to inhibit T4-to-T3 conversion (similar mechanism to PTU’s deiodinase inhibition) and to suppress the immune response in Graves’ ophthalmopathy. No direct drug interaction, but the combination is important in severe cases.
• Iodine-containing drugs and contrast agents: Iodine (e.g., potassium iodide, Lugol’s solution) and iodinated contrast media can provide large amounts of substrate for thyroid hormone synthesis. After the initial Wolff-Chaikoff effect (acute inhibition of hormone synthesis by high iodine levels), the thyroid gland typically escapes this inhibition after 2–3 weeks and can use the iodine to produce more hormone. Therefore, iodine should not be used as a long-term treatment, and its use must be carefully timed with antithyroid drugs.

Generic Pricing Comparison

Both methimazole and PTU are available as affordable generics, though PTU is less commonly prescribed and may have higher prices due to lower demand and smaller manufacturing volumes.

Methimazole generic pricing: In India, generic methimazole 10 mg tablets are manufactured by numerous pharmaceutical companies and are widely available. A pack of 10 tablets typically ranges from $1.50–$4 USD (approximately 120–330 Indian rupees). A pack of 30 tablets generally costs between $3–$8 USD. In the United States, brand-name Tapazole has largely been replaced by generic methimazole, which at retail pharmacies costs approximately $8–$20 for 30 tablets of 10 mg strength. Higher-dose regimens (e.g., 30 mg/day) would require 3 tablets of 10 mg daily, so the monthly cost at US retail prices for a 30 mg/day regimen would be approximately $24–$60 USD.

PTU generic pricing: In India, generic PTU (propylthiouracil) 50 mg tablets typically cost between $3–$8 USD (approximately 240–650 Indian rupees) for a pack of 10 tablets. A pack of 30 tablets generally ranges from $8–$20 USD. In the United States, generic PTU is more expensive than generic methimazole due to lower manufacturing volumes. A pack of 100 tablets of PTU 50 mg at US retail prices typically costs approximately $60–$120 USD, making a daily regimen of 300 mg/day (6 tablets) cost approximately $18–$36 USD per month. Brand-name Propacil is no longer commonly available.

Monthly cost comparison: For a typical treatment regimen, methimazole is significantly more economical than PTU. A patient on methimazole 20 mg once daily would spend approximately $6–$16 USD per month for generic methimazole at Indian prices and $8–$20 USD per month at US retail prices. A patient on PTU 300 mg/day (6 tablets of 50 mg daily) would spend approximately $18–$48 USD per month at Indian prices and $18–$36 USD per month at US retail prices. The cost difference is primarily driven by the higher number of tablets required for PTU due to its multiple-daily-dosing requirement.

To explore available generic methimazole formulations, visit our thyroid product category for an overview of treatment options. For PTU generics, please consult with your healthcare provider regarding availability and appropriate sourcing.

Long-Term Management of Graves’ Disease

The management of Graves’ disease extends beyond simply prescribing an antithyroid drug. The three definitive treatment modalities for Graves’ disease are:

1. Antithyroid drugs (methimazole or PTU): Typically used for 12–18 months to induce remission. The hope is that during this time, the autoimmune process resolves and the patient remains euthyroid after drug discontinuation. However, relapse rates are high—approximately 50–70% of patients relapse within 1 year of stopping the drug, and the long-term remission rate after 18 months of treatment is only 30–50%. Factors associated with higher remission rates include mild disease, small goiter, and negative or low-titer TSIs at the end of treatment.
2. Radioactive iodine (I-131, RAI): A definitive treatment that destroys the overactive thyroid tissue. RAI is typically administered as a single oral dose and results in hypothyroidism in 80–90% of patients within 2–4 months, requiring lifelong levothyroxine replacement. RAI is contraindicated in pregnancy and breastfeeding and requires precautions to minimize radiation exposure to others. It is not recommended for patients with severe Graves’ ophthalmopathy, as it can worsen the eye disease—particularly in smokers.
3. Thyroidectomy (surgical removal of the thyroid gland): A definitive treatment reserved for specific scenarios: very large goiters causing compressive symptoms, suspected thyroid cancer, patients who cannot tolerate antithyroid drugs or RAI, and pregnant women who require treatment beyond the first trimester and cannot tolerate antithyroid drugs. Total thyroidectomy results in permanent hypothyroidism requiring lifelong levothyroxine. Surgical risks include damage to the recurrent laryngeal nerve (hoarseness, vocal cord paralysis) and the parathyroid glands (hypoparathyroidism, hypocalcemia).

The choice among these options depends on the patient’s age, disease severity, goiter size, presence of ophthalmopathy, pregnancy status, and patient preference. In many cases, antithyroid drug therapy is used as a bridge to definitive treatment (RAI or surgery) rather than as a long-term strategy.

FAQ

Q: Can I take methimazole and PTU together?

A: It is not standard practice to use both methimazole and PTU together for routine hyperthyroidism management. Using both simultaneously would increase the risk of side effects (especially agranulocytosis and hepatotoxicity) without clear evidence of additional benefit. In exceptional circumstances—such as severe Graves’ disease where a very rapid reduction in thyroid hormone levels is needed—a clinician might consider combination therapy, but this is unusual and would require close monitoring. The standard approach is to use one antithyroid drug and titrate the dose as needed, while also using beta-blockers for symptom control if necessary. In thyroid storm, the combination of PTU (or methimazole), iodine, corticosteroids, and beta-blockers is used, but this is a distinct emergency protocol, not routine therapy.

Q: Is methimazole safer than PTU?

A: In general, yes—methimazole is considered safer than PTU for long-term use in non-pregnant adults, due to its lower risk of severe hepatotoxicity and more convenient once-daily dosing. PTU’s higher risk of severe liver injury (including acute liver failure) has led to an FDA black box warning and a general recommendation to avoid PTU unless there are specific reasons to use it (first-trimester pregnancy, methimazole intolerance, or thyroid storm where its dual mechanism is desired). However, methimazole is not safe in the first trimester of pregnancy due to the risk of methimazole embryopathy, which is why PTU is the preferred drug during early pregnancy. Both drugs carry the risk of agranulocytosis, which requires vigilant monitoring for signs of infection.

Q: How long does it take for methimazole or PTU to bring thyroid levels back to normal?

A: Antithyroid drugs do not work immediately—they inhibit new hormone synthesis but do not remove the pre-formed hormone already stored in the thyroid gland. Thyroid hormone levels (free T4, total T3) typically begin to decline within 1–3 weeks of starting treatment, with normalization usually occurring within 4–8 weeks. TSH (thyroid-stimulating hormone) takes longer to normalize—typically 6–12 weeks or longer—because the pituitary gland’s response to changing thyroid hormone levels is slower. During the initial treatment phase, thyroid function tests are usually checked every 2–4 weeks to guide dose adjustments. Once euthyroidism is achieved, monitoring can be extended to every 3–6 months for stable patients.

Q: What should I avoid while taking methimazole or PTU?

A: Key precautions include: (1) Immediately report any signs of infection—especially sore throat, fever, or mouth ulcers—as these can be the first signs of agranulocytosis, a medical emergency. (2) Avoid excessive iodine intake (kelp supplements, iodine-containing multivitamins, seaweed snacks), as this can provide more substrate for thyroid hormone production and counteract the drug’s effect. (3) Avoid activities requiring alertness if you experience dizziness or drowsiness, especially during the initial treatment phase. (4) Do not stop the medication abruptly—even if you feel better—without consulting your doctor, as hyperthyroid symptoms can recur rapidly. (5) Women of childbearing age should use reliable contraception and discuss pregnancy plans with their doctor, as both drugs have different pregnancy safety profiles requiring careful management.

Q: Can hyperthyroidism be cured without medication?

A: Hyperthyroidism caused by Graves’ disease or toxic nodular goiter can be definitively treated without long-term medication by using radioactive iodine (RAI) therapy or thyroidectomy (surgical removal of the thyroid). RAI is the most common definitive treatment in the United States, while surgery is reserved for specific cases. Both result in permanent hypothyroidism, which is then managed with lifelong levothyroxine replacement—a much simpler and safer condition to manage than hyperthyroidism. However, these are not cures in the sense of restoring normal thyroid function without treatment—instead, they trade hyperthyroidism for hypothyroidism, which is easily controlled. Antithyroid drug therapy can sometimes lead to remission of Graves’ disease (estimated 30–50% after 12–18 months), where the patient remains euthyroid off medication, but this is unpredictable and relapse is common. Hyperthyroidism caused by subacute thyroiditis is typically self-limited and resolves without specific treatment, though symptoms may be managed with NSAIDs, beta-blockers, or temporary corticosteroids.

References

1. American Thyroid Association (ATA) Guidelines for the Treatment of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(3):1–27. — Current clinical practice guidelines.
2. Akaishi T, et al. “Antithyroid drug therapy for Graves’ disease in children and adolescents: a systematic review.” Journal of Pediatric Endocrinology and Metabolism. 2020;33(4):439–448.
3. Bahn RS, et al. “The American Thyroid Association Task Force on Hyperthyroidism. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.” Thyroid. 2011;21(6):593–646.
4. FDA. “Propylthiouracil (PTU) — Risk of Severe Hepatotoxicity.” Black Box Warning. Updated 2023. FDA-approved labeling.
5. FDA. “Methimazole — Risk of Embryopathy in Pregnancy.” Drug Safety Communication. Updated 2022.
6. McLachlan SM, et al. “Thyroid-stimulating immunoglobulins and Graves’ disease.” Endocrine Reviews. 2021;42(1):1–36.
7. Millo C, et al. “Propylthiouracil-induced hepatotoxicity: report of a case and review of the literature.” Journal of Clinical Endocrinology and Metabolism. 2019;104(3):759–765.
8. UpToDate. “Methimazole: Drug Information” and “Propylthiouracil: Drug Information.” Accessed September 2026.
9. Cooper DS. “Antithyroid drugs: 2021 update.” New England Journal of Medicine. 2021;385(2):156–165. — Comprehensive review of antithyroid drug therapy.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Methimazole and propylthiouracil (PTU) are prescription antithyroid medications that should only be used under the supervision of a qualified healthcare provider, ideally an endocrinologist. The choice between these medications depends on individual patient factors including pregnancy status, liver function, other medications, disease severity, and treatment history. Never start, stop, or change the dose of either antithyroid medication without consulting your physician—abrupt discontinuation can cause a rebound worsening of hyperthyroidism. Patients should immediately report any signs of infection (sore throat, fever) to their doctor, as this can indicate agranulocytosis, a rare but serious adverse effect. Prices mentioned are approximate ranges and may vary by manufacturer, pharmacy, and location. Generic medications sourced internationally should be verified for authenticity and quality through appropriate regulatory channels.